Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenji Hashimoto

Showing results (31-40 of 861) with videos related to

Pageof 87
Sort By:
Current Pharmaceutical Design|June 6, 2015
Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational BiomarkerKenji Hashimoto
Brain Research Reviews|June 2, 2009
Emerging role of glutamate in the pathophysiology of major depressive disorderKenji Hashimoto
Journal of Clinical Psychopharmacology|July 14, 2009
Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606 in patients with treatment-refractory major depressive disorder"Kenji Hashimoto
Clinical Chemistry|August 30, 2008
CSF serine enantiomers and glycine in the study of neurologic and psychiatric disordersKenji Hashimoto
Nihon Shinkei Seishin Yakurigaku Zasshi = Japanese Journal of Psychopharmacology|July 30, 2010
[Role of sigma-1 receptors in neural plasticity and in antipsychotic action]Kenji Hashimoto
Current Pharmaceutical Design|March 2, 2011
Novel potential therapeutic approaches for schizophreniaKenji Hashimoto
The American Journal of Psychiatry|October 4, 2016
Detrimental Side Effects of Repeated Ketamine Infusions in the BrainKenji Hashimoto
Biological Psychiatry|September 29, 2015
Minocycline and St. John's wort as therapeutic drugs for human tauopathyKenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience|January 6, 2021
Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptorKenji Hashimoto
Molecular Psychiatry|November 28, 2024
Evaluating the safety of orexin receptor antagonists on reproductive health and sexual functionKenji Hashimoto
Pageof 87

Showing results (31-40 of 861) with videos related to

Sort By:
Pageof 87
Current Pharmaceutical Design|June 6, 2015
Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational BiomarkerKenji Hashimoto
Brain Research Reviews|June 2, 2009
Emerging role of glutamate in the pathophysiology of major depressive disorderKenji Hashimoto
Journal of Clinical Psychopharmacology|July 14, 2009
Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606 in patients with treatment-refractory major depressive disorder"Kenji Hashimoto
Clinical Chemistry|August 30, 2008
CSF serine enantiomers and glycine in the study of neurologic and psychiatric disordersKenji Hashimoto
Nihon Shinkei Seishin Yakurigaku Zasshi = Japanese Journal of Psychopharmacology|July 30, 2010
[Role of sigma-1 receptors in neural plasticity and in antipsychotic action]Kenji Hashimoto
Current Pharmaceutical Design|March 2, 2011
Novel potential therapeutic approaches for schizophreniaKenji Hashimoto
The American Journal of Psychiatry|October 4, 2016
Detrimental Side Effects of Repeated Ketamine Infusions in the BrainKenji Hashimoto
Biological Psychiatry|September 29, 2015
Minocycline and St. John's wort as therapeutic drugs for human tauopathyKenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience|January 6, 2021
Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptorKenji Hashimoto
Molecular Psychiatry|November 28, 2024
Evaluating the safety of orexin receptor antagonists on reproductive health and sexual functionKenji Hashimoto
Pageof 87